Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Newly identified barrier cells seal off choroid plexus from CSF, rest of brain
A long-overlooked layer of fibroblasts exists inside the choroid plexus of mice and humans, adding complexity to the area’s compartmentalization.
Newly identified barrier cells seal off choroid plexus from CSF, rest of brain
A long-overlooked layer of fibroblasts exists inside the choroid plexus of mice and humans, adding complexity to the area’s compartmentalization.
‘Digital sphinx’ raises questions about connectome models
The sphinx, with a worm’s brain and a fly’s body, illustrates the potential pitfalls of using deep-learning techniques to model biological processes.
‘Digital sphinx’ raises questions about connectome models
The sphinx, with a worm’s brain and a fly’s body, illustrates the potential pitfalls of using deep-learning techniques to model biological processes.
Taking a closer look at astrocytes and autism
These glial cells are increasingly linked to neurodevelopmental conditions and the regulation of social behaviors and anxiety.
Taking a closer look at astrocytes and autism
These glial cells are increasingly linked to neurodevelopmental conditions and the regulation of social behaviors and anxiety.